TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer

(The Translational Genomics Research Institute) An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen. Ponatinib was found in TGen-led drug screens and preclinical studies to significantly delay tumor growth and reduce tumor volume in SCCOHT, according to the study published online in the scientific journal Clinical Cancer Research.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news